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Abstract: Despite more than a half century of “safe” cardio-
pulmonary bypass (CPB), the evidence base surrounding the
conduct of anticoagulation for CPB has not been organized into
a succinct guideline. For this and other reasons, there is enor-
mous practice variability relating to the use and dosing of
heparin, monitoring heparin anticoagulation, reversal of anti-
coagulation, and the use of alternative anticoagulants. To ad-
dress this and other gaps, the Society of Thoracic Surgeons
(STS), the Society of Cardiovascular Anesthesiologists (SCA),
and the American Society of Extracorporeal Technology
(AmSECT) developed an Evidence BasedWorkgroup. This was
a group of interdisciplinary professionals gathered together to
summarize the evidence and create practice recommendations
for various aspects of CPB. To date, anticoagulation practices in
CPB have not been standardized in accordance with the evi-
dence base. This clinical practice guideline was written with the
intent to ﬁll the evidence gap and to establish best practices in
anticoagulation for CPB using the available evidence. To
identify relevant evidence a systematic review was outlined and
literature searches were conducted in PubMed® using stan-
dardized MeSH terms from the National Library of Medicine list
of search terms. Search dates were inclusive of January 2000 to
December 2015. The search yielded 833 abstracts which were
reviewed by two independent reviewers. Once accepted into the
full manuscript review stage, two members of the writing group
evaluated each of 286 full papers for inclusion eligibility into the
guideline document. Ninety-six manuscripts were included in the
ﬁnal review. In addition, 17 manuscripts published prior to 2000
were included to provide method, context, or additional sup-
porting evidence for the recommendations as these papers were
considered sentinel publications. Members of the writing group
wrote and developed recommendations based on review of the
articles obtained and achieved more than two thirds agreement
on each recommendation. The quality of information for a given
recommendation allowed assessment of the level of evidence
as recommended by the AHA/ACCF Task Force on Practice
Guidelines. Recommendations were written in the three fol-
lowing areas 1) Heparin dosing and monitoring for initiation and
maintenance of CPB, 2) Heparin contraindications and heparin
alternatives, 3) Reversal of anticoagulation during cardiac op-
erations. It is hoped that this guideline will serve as a resource
and will stimulate investigators to conduct more research and
expand upon the evidence base on the topic of anticoagulation
for CPB. Keywords: cardiopulmonary bypass, heparin, hepa-
rin alternatives, protamine, anticoagulation reversal, bivalirudin.
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INTRODUCTION
The development of cardiopulmonary bypass (CPB) in
the 1960s so successfully enabled open heart surgery that
rigorous evidence based clinical trials did not play a part in
the initial phases of development (1). After World War II,
clinicians were faced with more and more treatment
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choices to the point that uncertainty existed about the
“best” options. Indeed Archie Cochrane recognized the
need for amore rigorous approach to give clinicians answers
to key questions about patient treatments. Cochrane’s
efforts eventually led to the formation of the Cochrane
Collaboration, as a repository of evidence based summaries
to answer important clinical questions (2). As a result, the
modern era expects, and indeed requires, evidence to
support surgeons’ interventions, preferably in the form of
randomized controlled trials (RCTs). Over the last 60-plus
years since the introduction of clinical CPB as the foun-
dation for performance of cardiac operations, surgeon
investigators developed a safe, efﬁcient, and reproducible
method of performing highly complex cardiac procedures
using CPB. Many advances in CPB are the result of
evidence-based RCT’s. Others derive from prospective
cohort studies and still others, from anecdotal practice or
consensus.
Recognizing this large scope of practice and the varied
nature of the evidence base to support the use of CPB, the
Evidence Based Workforce of the Society of Thoracic
Surgeons (STS) undertook a project to develop a series of
practice guidelines that reﬂect the evidence base for the
use of CPB in the current era. This effort included
a collaboration with the Society of Cardiovascular An-
esthesiologists (SCA) and with the American Society of
Extracorporeal Technology (AmSECT) to summarize
available evidence in various areas of CPB. A critically
important part of CPB is the use of anticoagulation. To
date, there are no evidence-based practice guidelines that
deﬁne the optimal management of anticoagulation during
the conduct of CPB. As a result, practice in this area is
highly variable and not standardized in accordance with
the evidence base to date. Thus, The STS recognized this
deﬁcit and undertook a collaboration with the SCA and
the AmSECT to address the evidence gap regarding the
use of anticoagulation during CPB. This article reviews
relevant published information about the use of anti-
coagulation for the conduct of CPB and provides a syn-
thesis of the available evidence to create a clinical practice
guideline. This guideline represents the initial evidence
based approach to the use of anticoagulation in CPB and
is the only available comprehensive guideline of its kind. It
is the hope of the authors that this guideline will stimulate
investigators to amplify and elaborate upon the evidence
available on this topic.
Search Methods
To identify relevant evidence a systematic review was
outlined and literature searches were conducted in
PubMed® using standardized MeSH terms from the Na-
tional Library of Medicine list of search terms and were
inclusive of dates January 2000 up to December 2015. The
following terms comprised the standard baseline search
terms for topics and were connected with the logical OR
connector:
 Extracorporeal circulation (MeSH number E04.292 in-
cludes ECMO, left heart bypass, hemoﬁltration, hemo-
perfusion & cardiopulmonary bypass).
 Cardiovascular surgical procedures (MeSH number
E04.100 includes OPCAB, CABG, myocardial re-
vascularization, all valve operations, and all other op-
erations on the heart).
 Pharmacologic actions of anti-coagulant drugs (MeSH
number D27.505 includes molecular mechanisms, phys-
iologic effects, and therapeutic use of drugs).
 Anticoagulation reversal (MeSH number D12.776 in-
cludes protamine sulfate and other protamines and
nuclear proteins).
These broad search terms allowed speciﬁc topics to be
added to the search with the logical “AND” connector and
publication types and group to be excluded (see Appen-
dix). This search methodology provided a broad list of
generated references speciﬁc for the search topic. The
searches yielded 833 abstracts. Abstracts were reviewed by
two independent reviewers for acceptance into the paper
review stage. Abstracts with at least one acceptance were
sent to full manuscript review. A total of 286 full papers
were reviewed by at least twomembers of the writing group
for inclusion eligibility in the Guideline. In order to be
included, a paper had to report data on each of the fol-
lowing: 1) anticoagulant used for cardiopulmonary bypass
and 2) the monitoring techniques used to measure that
anticoagulation. After passing mandatory inclusion crite-
ria, it was preferable that included papers have a pro-
spective study design, and also report on the frequency of
anticoagulation monitoring, bleeding outcomes, and trans-
fusion outcomes. Ninety six manuscripts were included in
the ﬁnal review. In addition seventeen manuscripts pub-
lished prior to 2000, that were referenced within a manu-
script, and considered to be sentinel papers, were included
to provide method, context, or additional supporting evi-
dence for the recommendations.
Individual members of the writing group read the re-
trieved references for their assigned topics and formulated
recommendations based on assessment of the relevant
literature. Only English language articles contributed to the
ﬁnal recommendations. For almost all topics reviewed, only
evidence relating to adult patients entered into the ﬁnal
recommendations, primarily because of limited availability
of high quality evidence relating to pediatric patients having
cardiac procedures. Evidence tables were constructed in
order to ensure that selected studies conformed to minimum
requirements in terms of study design and reporting of out-
comes. A representative evidence table evaluating the Anti-
coagulation studies is shown in Supplemental Table 1 (online
only). Study appraisals of randomized controlled trials
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and meta-analyses are shown in Supplemental Table 2
(online only), and the Newcastle-Ottawa appraisal for
nonrandomized studies is depicted in Supplemental Table 3
(online only).
Duties of the Writing Group
Members of the writing group wrote and developed rec-
ommendations based on review of the articles obtained using
the search technique described above. The quality of infor-
mation for a given recommendation allowed assessment of the
level of evidence as recommended by the AHA/ACCF Task
Force on Practice Guidelines (http://www.americanheart.org/
downloadable/heart/12604770597301209Methodology_
Manual_for_ACC_AHA_Writing_Committees.pdf). Appen-
dix 1 contains a summary of recommendations put forth in this
guideline as a result of the evidence base.
HEPARIN DOSING FOR INITIATION AND
MAINTENANCE OF CPB
Class I Recommendation
A functional whole blood test of anticoagulation, in the
form of a clotting time, should be measured and should
demonstrate adequate anticoagulation before initiation of,
and at regular intervals during cardiopulmonary bypass.
(Level of Evidence C)
Class IIa Recommendations
 Bolus administration of unfractionated heparin based
upon weight is reasonable for achieving adequate
anticoagulation, but individual response to heparin is
heterogeneous and requires a therapeutic functional test
of clot inhibition before initiation of CPB, independent
of the bolus dose used. (Level of Evidence C)
 It is reasonable to use Activated Clotting Time (ACT)
tests that produce “maximally activated” clotting times
since these tests mitigate ACT variability, are less sus-
ceptible to hypothermia, and correlate more closely with
Factor Xa activity compared to tests that employ a single
activator. (Level of Evidence B)
 It is reasonable to maintain activated clotting time above
480 seconds during CPB. However this minimum
threshold value is an approximation and may vary based
upon the bias of the instrument being used. For in-
struments using ‘maximal activation’ of whole blood or
microcuvette technology, values above 400 seconds are
frequently considered therapeutic. (Level of Evidence
C)
Class IIb Recommendations
 Use of a heparin dose-response formula may identify
reduced sensitivity to heparin, but has not been shown to
be more useful than weight-based heparin dosing, in
determining the heparin dose required to achieve an
adequate ACT for initiation of CPB. (Level of Evidence
B)
 Use of heparin concentration monitoring in addition to
ACT might be considered, for the maintenance of CPB,
as this strategy has been associated with a signiﬁcant
reduction in thrombin generation, ﬁbrinolysis, and
neutrophil activation. However, its effects on post-
operative bleeding and blood transfusion are inconsistent.
(Level of Evidence B)
 During CPB, routine administration of unfractionated
heparin at ﬁxed intervals, with ACT monitoring, might
be considered and offers a safe alternative to heparin
concentration monitoring. (Level of Evidence C)
Activated Clotting Time (ACT) is considered the gold
standard in monitoring anticoagulation for CPB. The es-
tablishment of a safe or optimal range for ACT dates back
to data published in the 1970s when Bull et al. (3) showed
no development of clot in the oxygenator or circuit when
ACT was maintained above 300 seconds. However, Young
et al. (4) challenged this threshold when they demonstrated
ﬁbrin formation in the circuits of rhesus monkeys main-
tained on CPB with a minimum ACT value of 300 seconds,
and they recommended that this threshold value be in-
creased to 400 seconds by showing it was safe in ﬁve pe-
diatric patients on CPB. In order to maintain a margin of
safety above 400 seconds, the minimum acceptable ACT
value of approximately 480 seconds became a “standard of
care,” that was used inmultiple future studies and in clinical
practice, but was based on limited evidence. Despite this
widely accepted level of anticoagulation, there is no clear
consensus on the accurate calculation of this initial dose of
unfractionated heparin. Options for calculating the initial
heparin bolus include a ﬁxed, weight-based dose (e.g. 300
IU/kg), or use of point-of-care tests that measure the whole
blood sensitivity to heparin using an associated dose-
response.
In addition to the heterogeneity of heparin formulations
themselves, individual responsiveness to heparin is vari-
able. The pharmacodynamics of unfractionated heparin are
highly dependent on the level and function of plasma anti-
thrombin III (ATIII). In patients with preoperative hy-
percoagulability or reducedATIII responsiveness, increased
levels of circulating heparin are necessary to achieve
a therapeutic ACT value before CPB (5). Na and co-
authors reported signiﬁcant variations to heparin re-
sponsiveness in an observational study of patients with
known, stabilized infectious endocarditis. Garvin et al. (6)
also reported observed variations in heparin response in
patients having CPB. In a retrospective institutional da-
tabase review of 3,880 patients, these authors found wide
variation in the heparin bolus dose required to obtain
a target ACT. The initial unfractionated heparin bolus dose
J Extra Corpor Technol. 2018;50:5–18
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did not correlate well with the ﬁrst post-heparin ACT
(r2 5 .03).
The route and timing of the initial administration of
unfractionated heparin directly impacts the ability to obtain
a therapeutic ACT. A small randomized trial done by
Grima and colleagues found that intermittent doses of
unfractionated heparin administered beforeCPB (100 IU/kg
3 3 doses) maintained adequate levels of anticoagulation
during CPB better than a single bolus dose of 300 IU/kg (7).
Intermittent pre-CPB heparin treatment resulted in lower
mean decreases in factor VIII, ﬁbrinogen, ATIII, and
platelet count than if a large bolus dose were adminis-
tered. In a prospective non-randomized trial performed
by Neema et al. (8), six of the 100 patients that received
300 IU/kg of unfractionated heparin prior to CPB had
a resultant post-heparin ACT < 350 seconds. Other
pathological disturbances such as thrombocytosis may
limit the effectiveness of weight-based heparin bolus
administration.
Due to the heterogeneity of the pharmacodynamic re-
sponse to unfractionated heparin, the utilization of ex-vivo
heparin dose-response technologies was studied as a more
accurate prediction of initial heparin dosing. While ex-vivo
heparin dose-response technologies may identify patients
who have a reduced sensitivity to conventional doses of
heparin, these tests have limited ability to calculate cor-
rectly an optimal initial unfractionated heparin bolus dose.
The aforementioned observational study by Garvin et al
demonstrated poor correlation of the calculated in vitro
heparin dose response curve compared with the actual
patient heparin dose-response, resulting in a failure to
reach therapeutic ACT values in nearly 17% of pa-
tients (6).
During CPB, an overestimation of heparin concentration
may occur when using the ACT assay alone. Falsely ele-
vated ACT values may be observed under conditions of
hypothermia, reduced hemoglobin concentration, hypoﬁ-
brinogenemia, and pharmacologic agents that are not
associated with a concomitant increase in heparin con-
centration (9). In a controlled, non-randomized study of
42 patients, Machin et al. (10) demonstrated prolongation
of ACT values during hypothermic CPBwhen compared to
normothermic CPB. Leyvi et al. (11) reported similar ACT
prolongation under conditions of both hypothermia and
hemodilution using multiple ACT technologies while
plasma anti-factor Xa heparin level activity remained
constant. Maintaining ACT values during CPB without
heparin concentration monitoring may result in lower
doses of heparin. These known sensitivity limitations in
ACT monitoring may result in subclinical plasma co-
agulation occurring during CPB.
Whole blood heparin concentration assays are statisti-
cally more closely correlated with plasma anti-Xa levels
than the ACT (12). Clinically heparin concentration tests
are performed alongside a functional test of clotting, such
as an ACT, since a therapeutic functional conﬁrmation of
anticoagulation provides important safety data. In a ran-
domized controlled trial of 200 patients, Koster et al. found
that adhering to a heparin concentration maintenance
protocol led to a signiﬁcant reduction in thrombin gener-
ation, ﬁbrinolysis, and neutrophil activation, when com-
pared to ACT monitoring alone (480 seconds) (13).
Despotis et al. (14) randomized patients to ACT-based
(using 5,000 unit unfractionated heparin doses to maintain
ACT values >480 seconds) versus heparin concentration-
based management (with minimum ACT > 480 seconds),
and reported a higher heparin total dose in patients in the
heparin concentration group (6126 147 vs. 4626 114 U/kg,
p < .0001). Patients in the heparin concentration group
also had lower protamine to heparin ratios, and required
signiﬁcantly fewer blood product transfusions (platelets,
plasma, and cryoprecipitate) than the ACT-based control
group. Another randomized trial of 31 patients scheduled
for re-operative surgery resulted in signiﬁcant reductions in
perioperative blood loss and blood product usage when
maintaining higher patient-speciﬁc heparin dosing during
CPB (15). Another study found reduced platelet activation
and evidence of reduced thrombin generation with hepa-
rin concentration monitoring compared to routine ACT
monitoring (16). Together, these studies suggest that whole
blood heparin concentration monitoring results in larger
doses of unfractionated heparin during CPB and improved
hemostatic suppression compared to ACT monitoring
alone. However, these results did not translate into im-
proved clinical outcomes and have not been wholly re-
producible in the literature. A retrospective analysis in 686
patients favored ACT-based monitoring compared with
heparin concentration monitoring because of less post-
operative bleeding and transfusion requirements associ-
ated with ACT-based monitoring (17).
Traditionally, the gold standard for the measuring the
anticoagulant effects of heparin is inhibition of factor Xa
(anti-Xa) activity. Factor Xa is a major target for unfrac-
tionated heparin and can be readily measured in plasma
using laboratory assays. The various studies that seek to
validate a new measure of heparin’s activity, or a clotting
time assay, use anti-Xa activity as the gold standard
comparison. However, plasma assays for anti-Xa activity
are not ideally suited for point-of-care testing. Anti-Xa
measurement serves as a validating test for novel point-of-
care assays that reﬂect anti-Xa activity. Hansen et al. (18)
studied a whole blood modiﬁed ACT test and found it to be
highly correlated to laboratory anti-Xa measurement.
Helstern et al. (19) reported another one-step clotting
assay that correlates well with anti-Xa tests and is not
inﬂuenced by hemodilution, but clinical studies are lacking.
Routine re-dosing of unfractionated heparin at ﬁxed
intervals during CPB, despite a therapeutic ACT, is commonly
J Extra Corpor Technol. 2018;50:5–18
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used when heparin concentration assays are not available,
to simulate the practice of “higher heparin dosing.” This
practice prescribes additional ﬁxed doses of unfractionated
heparin at speciﬁc time points, even though ACT may be
above target. In a prospective trial of 100 patients pre-
senting for cardiac surgery, 1/3 of the initial heparin bolus
was administered at the 90-minute point of CPB, with
repeat doses every 60 minutes thereafter (8). This strategy
maintained adequate anticoagulation during the entire
period of hypothermic CPB; bleeding parameters were not
reported.
Despite the reported beneﬁts of higher heparin dosing,
other studies seemingly contradict these results. In a small
prospective trial of 21 patients, Gravlee et al. (20) con-
cluded that subclinical plasma coagulation occurs during
CPB despite heparin concentrations greater than 4.1 IU/mL.
Further, postoperative mediastinal chest tube drainage
correlates with increased heparin concentration, especially
if heparin rebound is not carefully monitored. A sub-
sequent, prospective study of 63 patients by Gravlee et al.
(21) showed that subjects who received an unfractionated
heparin bolus of 400 IU/kg and had heparin concentration
maintained >4 IU/mL did not differ in mediastinal
drainage or transfusion products from a control group of
patients receiving a bolus dose of 200 IU/kg plus additional
heparin for ACT values <400 seconds. A prospective trial
in 31 patients undergoing cardiac surgery revealed that all
patients had a residual circulating heparin level after
protamine administration (mean .18 IU/mL), detected by
a chromogenic anti-Xa assay. This residual heparin con-
centration did not correlate with ACT or whole blood
heparin concentration nor did it correlate with post-
operative mediastinal tube drainage volume (22). While
the studies supporting higher unfractionated heparin doses
are greater in size and number, the impact of using higher
doses of heparin on postoperative bleeding appears to be
unclear, especially if residual effects of heparin are not
detected or treated.
Documented therapeutic anticoagulation of patients
having CPB is necessary and is routinely performed using
an ACT. However, ACT devices vary considerably in their
measurement platforms, activators, sample volumes, and
sensitivities to external elements such as hemodilution,
hypothermia, and concomitant drug therapies (23,24). It
appears that arterial versus venous blood sampling and
a wait period up to 15 minutes do not signiﬁcantly impact
the ACT result (25,26). Currently there are many in-
struments and platforms available that purport to measure
ACT values. To rationally utilize an ACT device for pa-
tients undergoing CPB, it is important to understand how
the testing platform works, the therapeutic target that
corresponds to an historical ACT of 480 seconds, and how
well the results correlate with anti-Xa activity. In an early
study of heparin monitoring and ACT threshold values, it
was noted that the two most commonly used ACT devices
correlated with each other, yet there was signiﬁcant bias
with one of the instruments (27). Another observational
study showed that many ACT tests correlated poorly with
heparin level as assessed by anti-Xa plasma activity (28).
Patteril et al. (29) demonstrated that after switching their
cohort population to a newer ACT device, the new in-
strument yielded a lower mean ACT value compared with
temporal controls (557 vs. 618 seconds, p < .05) and
a higher dose of unfractionated heparin was needed to
achieve a minimum ACT of 480 seconds. A certain level of
validation has been performed for other ACT instruments
as well (30).
Tests that use a maximal degree of activation of the
blood sample by using multiple or more potent activators
produce shorter clotting times relative to the standard
ACT with a single activator (31). The tests that utilize
a maximally activated sample also report less variability in
clotting times, and are less susceptible to prolongation by
hypothermia and artifacts (32). The maximal activation
removes the variability induced by hemodilution of
clotting factors. Maximal activation is also accomplished
in the microcuvette ACT technology due to the small
sample volume and minimization of sample dilution. A
plasma supplemented-ACT accomplishes a similar result.
This test has been shown to mitigate the ACT variability
to more closely mirror anti-Xa levels, however it is
cumbersome and difﬁcult to perform at the point of
care (19).
The viscoelastic tests have been modiﬁed for point-of-
care measurement of the ACT and in a small ex vivo
analysis in CPB patients, the two tests performed similarly
to standard ACT tests with respect to heparinization and
hemodilution (30,33). Another observational study in 50
CPB patients demonstrated that a viscoelastic measure-
ment of ACT activity mirrored the activity of both standard
ACT tests and anti-Xa levels (34). It remains uncertain
what the threshold minimum safe values are for the vis-
coelastic clotting times in CPB and how they correspond
with the historical 480 seconds target. Further clinical and
outcome studies are warranted before switching patient
management to a viscoelastic ACT test.
HEPARIN CONTRAINDICATIONS &
HEPARIN ALTERNATIVES
Class IIa Recommendations
 Clinical scoring estimates that use a fall in platelet count
greater than 50% and/or a thrombotic event between 5
and 14 days following a heparin exposure can be used to
determine whether a heparin-platelet antibody test
should be performed to diagnose heparin-induced
thrombocytopenia (HIT) (Level of Evidence B)
J Extra Corpor Technol. 2018;50:5–18
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 Serum tests that include functional testing with sero-
tonin release assay (SRA) or heparin-induced platelet
activation (HIPA) can be beneﬁcial in identifying pa-
tients with HIT who have a history of thrombocytope-
nia, and elevated clinical HIT risk scores, when PF4/
heparin antibody testing is inconclusive (weakly posi-
tive) for HIT. (Level of Evidence C)
 In patients who are seropositive for heparin-platelet
antibodies or have a recent history of HIT, it is rea-
sonable to delay elective cardiac operations requiring
CPB until a patient’s functional test and/or antigenic
(antibody) assay are negative, with the expectation that
heparin anticoagulation for CPB is likely to be safe and
effective. (Level of Evidence C)
 In patients with a diagnosis of HIT and in need of an
urgent operation requiring CPB, anticoagulation with
bivalirudin is a reasonable option. (Level of Evidence
B).
Class IIb Recommendation
• In patients with signiﬁcant renal dysfunction who are se-
ropositive for HIT and require urgent operation requiring
CPB, use of plasmapheresis, argatroban, or heparin with
antiplatelet agents (such as tiroﬁban, ilioprost) may be
considered, understanding that there are increased risks of
bleeding with these interventions. (Level of Evidence C).
The chief contraindications to the use of heparin for
cardiopulmonary bypass are a history of heparin-induced
thrombocytopenia (HIT) and known hypersensitivity to
heparin. Whereas HIT is characterized by the development
of IgG antibodies recognizing platelet factor 4 (PF4)-
heparin complexes (35,36), hypersensitivity reactions to
heparin can be Type I, II or IV (37,38). HIT with or without
thrombosis occurs in patients who form PF4-heparin im-
mune complexes capable of activating platelets (39,40).
The presence of these anti-PF4/heparin antibodies forms
the basis for the clinical antigenic (ELISA) assay for HIT
(39). Although the presence of PF4-heparin complexes
following heparin exposure can be quite high (>30% in
surgical patients), the incidence of HIT is much lower
(1–2%) (41–45). Patients who test positive (antigen assay)
for anti-PF4-heparin antibodies preoperatively appear to
have a higher overall risk for complications and increased
mortality following cardiac surgery (46–48). Given the
60–90 days amnestic period for HIT antibodies, postponing
elective cardiac surgery in patients with elevated PF4-
heparin antibodies could potentially mitigate this avoid-
able risk (49–52). Platelet count monitoring is currently
recommended for patients with heparin exposure prior
to cardiac surgery (e.g. cardiac catheterization or DVT
prophylaxis) to determine whether further testing is
indicated (45).
Detection of PF4-heparin antibodies that activate
platelets and trigger serotonin release requires a highly
speciﬁc and sensitive functional test for HIT (53). Func-
tional testing with serotonin release assay (SRA) or
heparin-induced platelet activation (HIPA) detect only
those IgG antibodies capable of activating platelets (45).
Thrombocytopenia and/or thrombosis are much more
likely when platelet activation occurs. Speciﬁc tests of
platelet serotonin release can be particularly helpful when
low-levels of positivity are detected using HIT antibody
(antigen) assays, which are sensitive, but not speciﬁc to
platelet activation (39,53).
HIT is a clinicopathologic diagnosis (54). The spectrum
ranges from formation of anti-PF4/heparin antibodies to
increasing degrees of thrombocytopenia due to platelet
activation and in its most severe form diffuse deposition of
platelet-related thrombi into microcirculation and extreme
depletion of circulating platelets. In a single-center ob-
servational study of 1,722 patients undergoing cardiac
surgery, HIT was suspected in 63 (3.6%) and conﬁrmed in
24 (1.4%) (55). Validated clinical scoring systems can guide
initial decision-making and laboratory testing (39,55–59).
These scoring methods take into consideration the char-
acteristic temporal relationship of the onset of thrombo-
cytopenia (6 thrombotic event) to heparin exposure
(5–14 days) (60), the percent decrease in platelet count
(>30–50%) and absolute level of platelets (20–100,000/
mL), in addition to duration of CPB, and other potential
contributory causes of thrombocytopenia (57,59). The
negative predictive value (for HIT) for those with a low
clinical scores is 98% (range 97–100%) (58,59). As such,
additional serological testing and delays in heparin anti-
coagulation and/or complications associated with heparin
alternatives in these patients can be avoided.
The positive predictive value (PPV) of the anti-heparin-
PF4 (ELISA) assay for HIT is very low (2–15%) (61,62).
As such, this assay should be limited to those with higher
pre-test probabilities (for HIT) found in those with in-
termediate (PPV of 10–20%) or high (PPV of 40–80%)
clinical scores. This usually occurs when the fall in platelet
count exceeds 50%, and/or a thrombotic event occurs
between postoperative days 5 and 14. Those with low
antibody titers (OD < .4) would be candidates for heparin
anticoagulation without further intervention given the high
sensitivity (90–98%) of this clinical assay (45,53). Post-
operatively, close monitoring of platelet counts are rec-
ommended and screening for HIT antibodies considered
if clinical scores indicate further serological testing is
warranted.
Patients with mild elevations in anti-heparin-PF4 titers
(OD .4–1.0) should have further serologic testing using
a functional assay especially if their clinical scores are in the
intermediate or high ranges (39). The high sensitivity
(90–98%) and speciﬁcity (80–97%) of the functional assays
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(SRA/HIPA) make them the gold standard for diagnosing
HIT (63). Negative SRA/HIPA frequently occurs in pa-
tients with elevated antibody titers using the clinical anti-
gen (ELISA) assays due to the presence of heparin-PF4
antibodies that do not activate platelets or cause throm-
bocytopenia and/or thrombosis (35). Patients with high
clinical scores and high antibody titers (>OD 1.0) are
candidates for heparin alternatives when urgent operations
preclude the use a functional (SRA/HIPA) assay.
True hypersensitivity to heparin is rare, yet can occur in
those allergic to heparin or their sources of heparin (e.g.
porcine or bovine sources of heparin) (37,38,64–66). Pa-
tients with a clinical suspicion for hypersensitivity to
heparin should undergo testing to conﬁrm the diagnosis as
soon as possible given the often urgent need for heparin
anticoagulation in a variety of clinical settings (37).
The decision to utilize an alternative anticoagulant
during CPB is based on the urgency of the cardiac pro-
cedure and the presence of heparin antibodies capable of
activating platelets. The American College of Chest Phy-
sicians recommends delaying non-urgent cardiac pro-
cedures until heparin antibodies are no longer detectable
(45). The single most cumbersome aspect of heparin al-
ternatives is inability to rapidly reverse anticoagulation
after weaning fromCPB. For nearly all heparin alternatives
there is no reversal agent equivalent to protamine. Other
negative side effects include prolonged operative times and
the risk of increased blood loss and transfusion. Although
several agents have been used as alternates to heparin
(47,54), there is only sufﬁcient data on bivalirudin to make
recommendations in this clinical setting.
Bivalirudin: Bivalirudin, a recombinant direct thrombin
inhibitor, is not currently approved by the Food and Drug
Administration for use during CPB (albeit approved for
this use outside of the United States). Bivalirudin effec-
tively inhibits the coagulation cascade and has a short 25
minutes half-life in patients with normal renal function.
Monitoring of anticoagulation with bivalirudin is more
challenging than with heparin. The ecarin clotting time
(ECT) correlates strongly (R2 5 .91) with therapeutic
bivalirudin concentrations but is not commonly available as
a point-of-care test (67). In a comparative analysis study of
10 patients undergoing cardiopulmonary bypass, three
different methods of the ACT test were compared to the
ECT (68). While not as accurate as the ECT, the more
commonly available celite ACT was found to have an
acceptable correlation to ECT determined bivalirudin
concentration (R2 5 .93).
Bivalirudin has the broadest experience in patients un-
dergoing cardiac surgery (with and without CPB) and in
those with HIT and thrombosis (HITT) requiring CPB
(69). This includes procedures requiring deep hypother-
mic circulatory arrest (70). Controlled trials suggest that
bivalirudin provides adequate anticoagulation in all pa-
tients (71,72). In these trials secondary end points including
mortality, 24-hour blood loss, overall incidence of trans-
fusions, and duration of surgery were similar in bivalirudin-
treated patients and in patients having CPB with heparin
anticoagulation and protamine reversal. Several studies
(EVOLUTION-ON, CHOOSE-ON) propose a reliable
therapeutic protocol for bivalirudin (71,72). Bivalirudin
dosing in the CHOOSE-ON and EVOLUTION-ON trial
included a loading dose of 1.0 mg/kg, infusion of 2.5 mg/kg/h
and pump prime of 50mg. The adequacy of anti-
coagulation was monitored using 2.5 times the baseline
activated clotting time (ACT). In many centers, target
ACT levels were achieved with lower loading dose and
infusion rates.
In the EVOLUTION-ON multi-center, open label trial,
101 patients were randomized to either bivalirudin or
heparin with protamine reversal. Both groups were suc-
cessfully anticoagulated and there were no signiﬁcant
differences in morbidity or mortality between groups at
7 days, 30 days or 12 weeks. Postoperative blood loss was
statistically higher at 2 hours (238 vs. 160 mL; p 5 .0009),
but not at 24 hours (793 vs. 668 mL; p5 .15). Postoperative
re-exploration occurred in 6.1 vs. 1.9%, but was not sta-
tistically signiﬁcant (72). Anticoagulation with the direct
thrombin inhibitor bivalirudin appears to provide a safe
and effective alternative to heparin and protamine reversal,
even though it may increase the risk of excessive bleeding.
In extreme cases, a combination of modiﬁed ultraﬁltration,
hemodialysis and administration of recombinant factor
VIIa, in addition to balanced hemostatic resuscitation with
fresh frozen plasma, cryoprecipitate and platelets may be
required until the anticoagulants effects of bivalirudin are
reversed (70,73,74).
Other alternatives to heparin: Other strategies for
anticoagulation in patients with HIT consist of reintro-
duction of heparin following either the removal of PF4-
heparin antibodies (plasmapheresis), administration of
intravenous anti-platelet therapy, or use of argatroban. The
use of plasmapheresis is generally limited to those with
weakly positive ELISA results requiring urgent cardiac
procedures (75–77). While each approach appears to be
safe and effective, there is insufﬁcient evidence for a rec-
ommendation in the setting of CPB.
In a small case series by Welsby et al. (76), 11 patients
with recent (<2 months) diagnosis of HIT received ther-
apeutic plasma volume exchange after induction of anes-
thesia. All patients had a reduction in antibody titers (range
of reduction: 50–84%). Of these 11 patients, two patients
had positive HIT antibodies at the time of operation. One
patient suffered an ischemic foot, likely related to an intra-
aortic balloon pump. Three (27%) died in the post-
operative period (range: 3 months to 1 year) although none
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of the deaths were attributed to HIT thrombosis. Other
case reports and smaller series are summarized in a practice
guideline by the American Society for Apheresis, although
recommendations regarding CPB are limited (54,75).
Iloprost (prostacyclin analogue) was used in several
studies of HIT patients in order to inhibit platelet acti-
vation during cardiac surgery (78). In a large retrospective
analysis of 1,518 consecutive cardiac surgery patients,
Palatianos et al. (79) identiﬁed 10 patients with clinical
symptoms of HIT with heparin-PF4 antibodies and
compared them to 10 randomly selected controls. Patients
presenting with HIT received a protocol of iloprost in-
fusion, supplemented with norepinephrine as needed, in
conjunction with heparin. The postoperative reduction in
platelet count was less in the iloprost group (12.56 8.7%)
vs. the control (38.1 6 15.2%) and no thrombotic com-
plications were detected. In another small study (n 5 10)
by Koster et al. (80), heparin was used in conjunction with
a tiroﬁban infusion during CPB. There was no clinical or
laboratory (D-Dimer) evidence of thrombosis or exces-
sive bleeding.
The use of argatroban has been reported in patients
requiring renal replacement therapy given that renal
clearance is an important means of bivalirudin excretion
and inactivation, Argatroban should be limited to these
exceptional circumstances, given that excessive bleeding is
the norm (81–85).
Individuals who are seropositive for heparin antibodies
are at increased risk of both thrombosis and bleeding
(associated with heparin alternatives). Given the poten-
tially catastrophic thrombotic complication associated with
rapid-onset HIT in those with a recent history of HIT,
a very high level of vigilance is recommended in patients re-
exposed to heparin. These patients warrant careful sur-
veillance, thrombo-prophylaxis and possibly other special
treatments to manage the increased risk.
REVERSAL OF ANTICOAGULATION DURING
CARDIAC OPERATIONS
Protamine Dosing For Heparin Reversal
Class IIa recommendation: It can be beneﬁcial to cal-
culate the protamine reversal dose based upon a titration to
existing heparin in the blood, since this technique has been
associated with reduced bleeding and blood transfusion.
(Level of Evidence B)
Heparin is by far the most commonly used anticoagulant
during the conduct of cardiac operations, whether done
with or without CPB. The preeminent beneﬁt of heparin as
compared with other anticoagulants is the ability to reverse
its effect with protamine in a safe and expeditious manner.
The goals of successful anticoagulation during CPB include
limiting clotting and safely reversing the anticoagulation
effect during and at the conclusion of operation, re-
spectively. For the vast majority of operations performed
using CPB, heparin is the anticoagulant used and prot-
amine is the reversal agent. An important part of the
operation is to adequately remove all of the heparin effect
at the end of operation. There are at least three methods
commonly used to detect residual heparin effect after
protamine reversal: 1) activated clotting time (ACT)
measurement, 2) point-of-care testing using protamine ti-
tration of heparinized blood samples, and 3) thromboe-
lastography with or without heparinase. Comparisons of
these three methods suggest that ACT-based measure-
ments of residual heparin effect are the least accurate
means of detecting residual heparin effect (86,87).
Methods of heparin reversal are multiple and contro-
versy exists regarding the optimal strategy. Traditional
methods administer heparin based on body weight and
protamine based on the amount of heparin administered.
Certain methods of protamine administration depend on
titration of protamine to neutralize heparin in blood
samples at the end of CPB. The literature comparisons of
these methods are mixed with most reports (88–90), but not
all (91,92), favoring titration methods. A meta-analysis of
standard weight-based vs. titrated protamine dosing favors
titrated dose protamine for heparin reversal because of less
postoperative blood loss and decreased packed red blood
cell transfusion (93).
Two studies suggest that viscoelastic measurements are
useful indicators of adequate titrated heparin reversal
(94,95). These studies found that individualized heparin-
protamine titration decreased the protamine-to-heparin
ratio, improved post-CPB thromboelastometric hemo-
static parameters, and reduced the incidence of severe
blood loss compared with an ACT-based strategy. In ad-
dition, evidence supports the use of sequential heparin/
protamine titrations following CPB to further limit blood
loss and to provide adequate protamine reversal (88).
Protamine Overdose
Class IIa recommendation: It is reasonable to limit the
ratio of protamine/heparin to less than 2.6 mg protamine/
100 Units of heparin, since total doses above this ratio
inhibit platelet function, prolong ACT, and increase the
risk of bleeding. (Level of Evidence C)
It is possible to overdose patients with protamine. Excess
protamine inhibits platelet function and prolongs the ACT
after CPB. Two studies provide convincing evidence that
when the ratio of protamine to heparin (mg protamine/100
Units heparin) is above 5:1, platelet aggregation and
function are impaired (96,97). In addition, Mochizuki et al.
(96) demonstrated that at ratios above 2.6:1, the ACT
signiﬁcantly increases. The European Association of
Cardiothoracic Surgery identiﬁed a ratio of 2.6:1 of prot-
amine to heparin as risking excessive bleeding. Their
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guidelines recommend limiting protamine, preferably using
a titration method, after the completion of CPB (98).
Heparin Rebound
Class IIb recommendation: Because of the risk of
heparin rebound in patients requiring high doses of heparin
and with prolonged CPB times, low dose protamine in-
fusion (25 mg/h) for up to 6 hours after the end of CPBmay
be considered as part of a multimodality blood conserva-
tion program. (Level of Evidence C)
Heparin rebound occurs when detectable heparin blood
levels are present at some remote time after apparently
adequate heparin reversal with protamine. This likely
occurs because of the ability of large molecules of heparin
to sequester in fat stores and plasma proteins with eventual
reappearance in the blood at some time after protamine
neutralization. Heparin dosing in excess of 400 IU/kg can
result in heparin rebound. High heparin dosing during CPB
results in higher doses of protamine required for reversal.
Randomized comparisons of high and low-dose heparin
for CPB suggest that heparin rebound increases with high
dose heparin (21). One study suggests that 10–15% of
patients receiving usual heparin doses for CPB will have
detectable heparin levels two hours after protamine re-
versal (99). Another study ﬁnds that detectable heparin
levels, measured using both anti-Xa and viscoelastic pa-
rameters, are present immediately, two hours, and four
hours after protamine administration (22).
Usual methods of monitoring heparin reversal and mea-
suring postoperative coagulation (e.g. ACT and APTT) do
not detect residual heparin levels (86,100). A randomized
trial involving 300 patients showed that a continuous infusion
of protamine following initial protamine reversal (25 mg/h
for 6 hours) abolishes heparin rebound and results in mod-
est, but signiﬁcant, reductions in chest tube blood loss but not
transfusion requirements (101).
Complications Associated with Protamine Reversal of
Heparin after CPB
Class I recommendation: In patients at high risk for
anaphylactic response to protamine who experience pul-
monary hypertension and circulatory collapse shortly after
protamine administration, discontinuation of protamine
and implementation of resuscitative measures including
reinstitution of CPB with adequate anticoagulation may be
lifesaving. (Level of Evidence C)
As one might expect with any drug, there are side effects
and complications associated with the use of protamine to
reverse the effects of heparin after CPB. A unique feature
of these complications associated with CPB is that they
occur at a crucial time of the operative procedure. Life-
threatening complications associatedwith protamine include
anaphylaxis, pulmonary edema and pulmonary hyperten-
sion (102). Life threatening cardiovascular compromise after
intravenous protamine can occur even in young infants
(103). These complications are associated with operative
mortality and serious organ dysfunction (104,105). It is
likely that protamine complications are under- reported
(102,106). A comprehensive review of the literature sug-
gests true anaphylactic reactions to protamine are rare (less
than one percent of patients having CPB), (102) and about
60% occur before CPB, likely related to other drugs used in
preoperative preparation of patients (e.g. antibiotics or
gelatin solution) (107). The results from this limited da-
tabase of anaphylactic reactions showed that cardiac sur-
gery proceeded without complications after cardiovascular
collapse caused by pre-CPB anaphylactic or anaphylactoid
reactions. Rapid institution of cardiopulmonary bypass
may be lifesaving in this setting (108).
Catastrophic cardiovascular reactions to protamine are
nitric oxide/cyclic guanosine monophosphate dependent
and endothelium mediated. This suggests that methylene
blue may be the treatment of choice in this setting but
high level evidence to support this intervention is lacking
(108). Evidence to date suggests that the site of protamine
administration does not inﬂuence the incidence of protamine-
induced pulmonary vasoconstriction, and aspirin inges-
tion within 1 week of surgery may decrease it (109).
Additionally, acute right ventricular failure and pulmo-
nary hypertension often precede catastrophic reactions
to protamine (105,110,111). Prostacyclin and bradykinin
B2 attenuate the acute pulmonary hypertension in this
setting but, again, no high level evidence supports the
use of these agents to reverse the early stages of a reaction
to protamine (110,112). What is known is that serious
protamine reactions predispose to operative mortality
and discontinuation of protamine and re-institution of CPB,
if serious protamine reactions occur, may be lifesaving
(105,107).
Studies show that antibodies to the protamine/heparin
complex occur commonly after CPB (113,114). These
antibodies share a number of serologic features with HIT-
derived antibodies, including platelet activation. Addi-
tionally, these protamine/heparin antibodies cross-react
with protamine-containing insulin preparations (113).
Development of these antibodies predisposes to adverse
outcomes following cardiac procedures and may pose risks
of anamnestic response upon re-exposure to protamine
(113,114). For example, a meta-analysis of the surgical
literature showed the risk of a protamine reaction in sur-
gical patients to be 10–20 times higher in patients taking
protamine-containing insulin compared to control patients
not taking insulin preparations (109,115).
Alternate Agents Used to Reverse Heparin
Anticoagulation
Reversal of heparin with protamine affects platelet ag-
gregation andwhole blood clotting (96). The overwhelming
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convenience of protamine reversal of heparin makes it the
drug of choice for heparin neutralization despite potential
adverse effects on platelet and clotting function. There are
patients who are unable to receive protamine for various
reasons. For this reason, PF4 has been investigated as
a heparin reversal agent in ex-vivo animal studies, and
occasional case reports (116–118). PF4 is released by ac-
tivated platelets and has strong attraction for heparin.
Studies show that recombinant PF4 provides adequate
heparin neutralization. However, pre-formed antibodies
against PF4/heparin complex are important contributors to
the pathophysiology of HIT. Patients previously exposed to
heparin may have these pre-formed antibodies and addi-
tion of exogenous PF4 in the presence of heparin risks an
anamnestic response and severe HIT and/or HITT. More
clinical experience is required to validate the safety of PF4
for heparin reversal after CPB (118).
Reports document attempts at using other drugs for
heparin neutralization. Methylene blue, hexadimethrine,
vancomycin, and heparinase I are among drugs tested for
heparin neutralization (117,119,120). None of these drugs
proved equivalent to protamine in its safety proﬁle for
reversal of heparin after CPB. One of these drugs, hep-
arinase I, was compared to protamine in a multicenter,
randomized, prospective trial. Heparinase I had an inferior
safety proﬁle following reversal of heparin at the end of
CPB which was a result of increased transfusion and
prolonged hospital stay in the heparinase group compared
to the protamine group (120).
At this time, protamine is considered the gold standard
for reversal of heparin anticoagulation. If protamine cannot
be used, there are not enough data to make a recommen-
dation regarding safety and efﬁcacy of any of the alter-
native heparin reversal agents.
Anticoagulation reversal when using heparin alternatives
and direct thrombin inhibitors
Class IIb recommendation: In patients requiring anti-
coagulation with bivalirudin who experience excessive
bleeding after CPB, a combination of modiﬁed ultraﬁl-
tration, hemodialysis, and the administration of recombi-
nant factor VIIa with blood product replacement may be
considered to improve hemostasis in these extreme situa-
tions. (Level of Evidence C)
The ideal anticoagulation strategy for cardiac surgery
with CPB in patients who cannot take heparin does not
exist. Heparin and protamine remain the gold standard for
anticoagulation therapy. A small subset of patients requires
heparin alternatives for the conduct of CPB. Bivalirudin
seems to offer the safest heparin alternative in this setting.
This drug has a short half-life of approximately 25 minutes.
Nonetheless, coagulopathy occurs in bivalirudin treated
patients. There is no well-deﬁned reversal agent for
bivalirudin, and patients with coagulopathy and excessive
bleeding require unusual interventions for hemorrhage
control. Only anecdotal experience is available to address
coagulopathy in bivalirudin-related hemorrhage (70,73).
Consensus suggests that a multifaceted approach offers the
best chance of successful hemorrhage control in these
patients. Recombinant activated Factor VII may be an
important part of hemorrhage control but other inter-
ventions including modiﬁed ultraﬁltration, hemodialysis,
and clotting factor replacement are also advocated (73).
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APPENDIX 1: EXECUTIVE SUMMARY OF
RECOMMENDATIONS
A functional whole blood test of anticoagulation, in the
form of clotting time, should be measured and should
demonstrate adequate anticoagulation before initiation of
and at regular intervals during cardiopulmonary bypass
(CPB). (Class I, Level of Evidence C).
Bolus administration of unfractionated heparin based
upon weight is reasonable for achieving adequate anti-
coagulation, but individual response to heparin is het-
erogeneous and requires a therapeutic functional test of
clot inhibition before initiation of CPB, independent of
the bolus dose used (Class IIa, Level of Evidence C).
It is reasonable to use activated clotting time (ACT) tests
that produce “maximally activated” clotting times because
these tests mitigate ACT variability, are less susceptible to
hypothermia, and correlate more closely with Factor Xa
activity compared with tests that employ a single activator
(Class IIa, Level of Evidence B).
It is reasonable to maintain ACT above 480 seconds
during CPB. However, this minimum threshold value is an
approximation and may vary based upon the bias of the
instrument being used. For instruments using “maximal
activation” of whole blood or microcuvette technology,
values above 400 seconds are frequently considered ther-
apeutic (Class IIa, Level of Evidence C).
Use of a heparin dose-response formula may identify
reduced sensitivity to heparin, but has not been shown to be
more useful than weight-based heparin dosing, in de-
termining the heparin dose required to achieve an adequate
ACT for initiation of CPB (Class IIb, Level of Evidence B).
Use of heparin concentration monitoring in addition to
ACT might be considered, for the maintenance of CPB, as
this strategy has been associated with a signiﬁcant re-
duction in thrombin generation, ﬁbrinolysis, and neutrophil
activation. However, its effects on postoperative bleeding
and blood transfusion are inconsistent (Class IIb, Level of
Evidence B).
During CPB, routine administration of heparin at ﬁxed
intervals, with ACT monitoring, might be considered and
offers a safe alternative to heparin concentration moni-
toring (Class IIb, Level of Evidence C).
Clinical scoring estimates that use a fall in platelet count
greater than 50% and/or a thrombotic event between 5 and
14 days after a heparin exposure can be used to determine
whether a heparin-platelet antibody test should be per-
formed to diagnose heparin-induced thrombocytopenia
(HIT) (Class IIa, Level of Evidence B).
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Serum tests that include functional testing with serotonin
release assay or heparin-induced platelet activation can be
beneﬁcial in identifying patients with HIT who have
a history of thrombocytopenia, and elevated clinical HIT
risk scores, when platelet factor 4 (PF4)/heparin antibody
testing is inconclusive (weakly positive) for HIT (Class IIa,
Level of Evidence C).
In patients who are seropositive for heparin-platelet
antibodies or have a recent history of HIT, it is reason-
able to delay elective cardiac operations requiring CPB
until a patient’s functional test and/or antigenic (antibody)
assay are negative, with the expectation that heparin
anticoagulation for CPB is likely to be safe and effective
(Class IIa, Level of Evidence C).
In patients with a diagnosis of HIT and in need of an
urgent operation requiring CPB, anticoagulation with
bivalirudin is a reasonable option (Class IIa, Level of
Evidence B).
In patients with signiﬁcant renal dysfunction who are
seropositive for HIT and require urgent operation re-
quiring CPB, use of plasmapheresis, argatroban, or heparin
with antiplatelet agents (such as tiroﬁban and ilioprost)
may be considered, understanding that there are increased
risks of bleeding with these interventions (Class IIb, Level
of Evidence C).
It can be beneﬁcial to calculate the protamine-reversal
dose based upon a titration to existing heparin in the
blood because this technique has been associated with
reduced bleeding and blood transfusion (Class IIa, Level of
Evidence B).
It is reasonable to limit the ratio of protamine/heparin to
less than 2.6 mg protamine/100 Units of heparin because
total doses above this ratio inhibit platelet function, pro-
long ACT, and increase the risk of bleeding (Class IIa,
Level of Evidence C).
Because of the risk of heparin rebound in patients re-
quiring high doses of heparin and with prolonged CPB
times, low-dose protamine infusion (25 mg/h) for up to 6
hours after the end of CPB may be considered as part of
a multimodality blood conservation program (Class IIb,
Level of Evidence C).
In patients at high risk for anaphylactic response to
protamine who experience pulmonary hypertension and
circulatory collapse shortly after protamine administration,
discontinuation of protamine and implementation of re-
suscitative measures including reinstitution of CPB with
adequate anticoagulation may be lifesaving (Class I, Level
of Evidence C).
In patients requiring anticoagulation with bivalirudin
who experience excessive bleeding after CPB, a combina-
tion of modiﬁed ultraﬁltration, hemodialysis, and the ad-
ministration of recombinant factor VIIa with blood product
replacement may be considered to improve hemostasis in
these extreme situations (Class IIb, Level of Evidence C).
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